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Accreditation Statements
CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing
Medical Education (ACCME®) to provide continuing medical education for physicians. The Centers for Disease
Control and Prevention designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians
should only claim credit commensurate with the extent of their participation in the activity. 
CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education
by the American Nurses Credentialing Center's Commission on Accreditation.  This activity provides 1.0 contact
hours.
IACET CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU's for this 
program.
CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education 
contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This 
program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education 
Specialists (MCHES) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced 
level continuing education contact hours available are 0. CDC provider number 98614.
CPE: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy 
Education as a provider of continuing pharmacy education. This program is a designated event for pharmacists to 
receive 0.1 CEUs in pharmacy education. The Universal Activity Number is 0387-0000-16-102-L04-P and enduring 
0387-0000-16-102-H04-P. This activity is knowledge based.
AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0  hours of continuing 
education in jurisdictions which recognize AAVSB RACE approval. Please contact the AAVSB RACE program if you 
have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.
CPH:  The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) 
recertification credits and is authorized to offer 1 CPH recertification credit for this program.
Continuing Education Disclaimer
CDC, our planners, presenters, and their spouses/partners 
wish to disclose they have no financial interests or other 
relationships with the manufacturers of commercial products, 
suppliers of commercial services, or commercial supporters.
Planners have reviewed content to ensure there is no bias. 
This presentation will not include any discussion of the 
unlabeled use of a product or products under investigational 
use.
To Ask a Question
 Using the Webinar System
 “Click” the Q&A tab at the top left of the webinar tool bar
 “Click”  in the white space
 “Type” your question
 “Click” ask
 On the Phone
 Press Star (*) 1 to enter the queue
 State your name
 Listen for the operator to call your name 
 State your organization and then ask your question
Objectives
At the conclusion of this session, the participant will be able to:
 Describe the risk factors, endemic areas, and incubation period of 
hantavirus infection
 Identify the clinical presentation and methods to identify a patient 
with hantavirus in the clinical setting
 Understand the parameters of clinical management and critical care 
for patients with hantavirus
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Hantavirus Overview and Epidemiology
 Hantavirus global overview 
 US Epi summary 
 Diagnostics 
 Hantavirus surveillance in the US
Hantaviruses
• Bunyavirus family
• Primarily rodent reservoirs
• Human infection
– Inhalation of excreta
– Bites possible
• Hemorrhagic fever with renal syndrome (HFRS)
– Old-world hantaviruses (Seoul virus likely throughout world)
– Europe and Asia
• Hantavirus pulmonary syndrome (HPS)
– New-world hantaviruses
– Numerous pathogenic hantavirus species across North and South 
America


























































New World Hantaviruses 
A. Deer mouse (Sin Nombre virus)
B. White-footed mouse (New York virus)
C. Hispid cotton rat (Black Creek 
Canal virus)
D. Rice rat (Bayou virus)
Rodent Reservoirs of 
Pathogenic Hantaviruses in the US
From: Mills et al, Vector-Borne and Zoonotic Diseases 2009
Hantavirus Ecology
• Persons living or working in rural areas at 
increased risk
– Farmers
– Outdoor enthusiasts (camping, hiking)
– Opening/cleaning unfrequented buildings and spaces 
(summer homes, sheds, attics, etc.) 
• 20-40 cases reported annually, >95% exposed 
west of Mississippi River
– Importance of exposure & travel history
Hantavirus Pulmonary Syndrome 
Epidemiology
Hantavirus Pulmonary Syndrome 
U.S. Descriptive Demographics
Characteristic Total
Gender Male 401 (63%)
Female 236 (37%)
Race White/Caucasian 496 (78%)
American Indian 115 (18%)
African American 12 (2%)
Ethnicity Hispanic 127 (20%)
Outcome Fatal 229 (36%)
• Total of 637 cases between 1993 and 2015
• Mean age: 37 (range: 5 to 84)
Hantavirus Pulmonary Syndrome Cases 
In the U.S. 1993-2015
Annual HPS Cases and Fatality Rate 
in the U.S. 1993-2015
17
MacNeil A, Ksiazek TG, Rollin PE. Hantavirus pulmonary syndrome, United States, 1993–2009. Emerg
Infect Dis [serial on the Internet]. 2011 Jul [date cited]. http://dx.doi.org/10.3201/eid1707.101306
Cumulative HPS Cases by Month of 
Onset in the U.S.
Hantavirus Diagnostics
• Serology: Most common means of diagnosis in 
US; detects IgM & IgG
– Testing available through commercial and public 
health labs (state/federal)
• PCR: Detectable virus during acute phase
• Immunohistochemistry: postmortem detection 
of hantavirus antigen
Hantavirus Antibody Testing
• IgM & IgG develop rapidly after onset of 
symptoms– detectable at first test in nearly all 
HPS patients
• Cross-reactivity between different hantavirus 
species
• Commercial assay:
– False positive results possible; important to interpret 
results carefully
• CDC ELISA:
– Available through state & federal labs; highly sensitive 
& specific
HPS Surveillance
• HPS and hantavirus infection without pulmonary 
symptoms are nationally notifiable conditions
– Providers should contact local or state health department 
for awareness & assistance with diagnostic testing
– Environmental investigations may occur at exposure sites
– Access form at http://www.cdc.gov/hantavirus/pdf/hps_case-
report-form.pdf
HCPS: Incubation Period, Clinical 
Presentation and Course 
Gregory Mertz, M.D.
Professor of Internal Medicine 
University of New Mexico
June 30, 2016
Site of initial HCPS case cluster 
New Mexico, May 1993
Incubation period, Andes virus (ANDV) Infection, Chile
11 patients with 24-48 hrs of exposure in rural area













Mean:   18.3   days
Range:  10-34
Vial P, et al. Emerg Infect Dis 2006:12:1271-3. PMID: 16965713 
2012 Yosemite Sin Nombre Virus outbreak
Incubation: median 30.5 (range 20-49) days
Nunez JJ, et al. Emerg Infect Dis 2014;20:386.
Ferrés M, et al. J Infect Dis. 2007;195:1563-1571. PMID: 17471425
© 2007 by the Infectious Diseases Society of America
Detection of Andes virus (ANDV) RNA by reverse-transcription 
polymerase chain reaction (RT-PCR) in peripheral blood cells 
obtained from household contacts who were asymptomatic and 
seronegative at study entry
Infection with Hantavirus
viremia
























Day of illness  (0 = day of hospitalization)
Severe
Mild
* P=0.00003 on 
Day 0
Neutralizing Antibody Titer in HCPS
At hospital admission, patients who have a mild course of HCPS have
significantly higher anti-Sin Nombre virus (SNV) neutralizing antibody titers 
when compared to patients who have or progress to severe or fatal disease.










Prodrome 2-6 d Cardiopulmonary phase 5-6 days Convalescence months
HCPS Presentation
Deaths by hospital day among 104 
hospitalized HCPS cases in Chile
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Presumptive diagnosis in 
cardiopulmonary phase 
After the onset of pulmonary edema, the 
presence of 4 of 5 findings has a sensitivity 
of 96% and specificity of 99%
• Thrombocytopenia
• Myelocytosis
• Lack of significant toxic granulation in neutrophils
• Hemoconcentration
• More than 10% lymphocytes with immunoblastic
morphologic features
Koster F, et al. Am J Clin Pathol 2001;116:665-72. PMID: 11710682
Immunoblasts in HCPS appear early in 
cardiopulmonary stage
Presumptive diagnosis of HCPS in the 
CASG IV ribavirin trial
• In 24 subjects with suspected HCPS in the 
cardiopulmonary phase (with bilateral infiltrates 
and hypoxia), SNV infection was confirmed in 23 
(96%) with a presumptive diagnosis based on 
smear evaluation
• In 12 subjects with suspected HCPS in the 
febrile prodrome (with fever and 
thrombocytopenia), none had SNV infection. 
Mertz GJ, et al. Clin Infect Dis. 2004:1307-13.
Hantavirus:
A Tale of Mice and Men
Michelle Harkins, MD
Diagnostic Dilemma
• Patients may present with vague symptoms
• Return for CBC in 8-12 hours
• If platelet count is falling, call 1-800-272-2000 (at 
UNM Med Center), ask for Medical Critical Care
or ID physician on call to discuss
Triage and Treatment
• Key point: transfer patient prior to 
cardiopulmonary phase to tertiary care center, 
preferably one with ECMO 
• Don’t wait to stabilize
• AVOID fluid resuscitation
• Inotropes early
• Oxygen, try to avoid intubation
• Arrange air transport with ability for pressor 
initiation and to a center with ECMO capability
Call from outside provider via PALS 
with suspected Hanta Patient






Depending on likelihood 
and severity of disease, 
all could be awaiting the 
arrival of the patient.
Multidisciplinary Involvement in 
Treatment of HCPS
Ribavirin
• Given early in HFRS in China, 7-fold reduction in 
mortality risk
• Results in HCPS inconclusive 
– Does inhibit SNV in vitro
– Pre-treatment reduced deer mice sero-conversion
• in vitro and in vivo inhibition ANDV
– Provided protection in a lethal hamster model of 
HCPS
– ? Beneficial for post-exposure prophylaxis




















Mertz GJ, et al. Clin Infect Dis, 2004 (Nov 1);39:1307-1313.
Survival without ECMO 
Ribavirin versus Placebo Recipients
Vial P A et al. Clin Infect Dis. 2013;57:943-951
Kaplan-Meier survival analysis by treatment arm 
(methylprednisolone vs placebo) and severity at entry by 
sequential organ failure score (SOFA)
Immune serum
• Serum from survivors with neutralizing 
antibodies may combat the viremia present
• Hamster/rat/primate studies have shown passive 
protection from hantavirus challenge when given 
neutralizing Ab
• No controlled human trials
• Not available in the US
Safronetz, Plos One, Aug 2011
Management of HCPS
• Critical care management
• Monitor PaO2/FiO2, cardiac index, lactate
• Pressors rather than IV fluids
• If ECMO is available, 
– Early placement of vascular sheaths
– Concurrent intubation and initiation of ECMO if 
medical management fails
• No role for ribavirin or methylprednisolone 
(ineffective in placebo-controlled trials)
Why ECMO for HCPS?
• Early experience showed short duration of 
critical condition
• Autopsy findings without tissue damage-
circulating inflammatory mediators likely cause 
cardiopulmonary dysfunction
• Occurs in previously healthy patients
Criteria for ECMO
• < 65 years of age
• No major organ system failure (cirrhosis, ESRD, 
neurologic dysfunction)
• HCPS by history, clinical judgment, smear
• CI<2.5 despite resuscitation or rapidly declining 
clinical status
• Hypotension
• Hypoxemia – PaO2/FiO2 <50 despite support
UNM Memo; Crowley, Crit Care Med, 1998
HCPS-ECMO Cannulation
• Femoral site-venoarterial
venous- 27- 29 french
arterial- 16-18 french
• Distal perfusion cannula – via posterior tibial
artery
• Open vs. percutaneous- surgeon’s preference




ECMO Machine in Use
Typical ECMO Course
• Patient paralyzed and sedated
• Ventilator settings ~ SIMV 10/500cc/40%/10
• Hemodynamic improvement 12 hours
• Pulmonary improvement 48-72 hours
• Weaning from ECMO 4-5 days when pulmonary 
capillary leak resolves and cardiac function 
improves
Crowley, Crit Care Med, 1998
UNM Hanta Stats
• From 2000 to 5/16 
– Approximately 75 patients Hanta +, not all needed 
ECMO
• Several patients with HCPS died prior to or 
during transport to UNM
– 2 within the last few months
• From Four Corners area
– One presented with GI complaints first day 
then represented next day in shock
– Other one presented late
UNM ECMO Hanta Stats
• Total 59 patients: 04/15/1994 – 3/29/16
– Survived ECMO  43/59 (73%)
– Survived to hospital discharge 37/59(63%)
• Age range 9 - 69
• Male 32, Female 27
• Duration of ECMO 5-276 hours (143)
New Mexico 
To Ask a Question
 Using the Webinar System
 “Click” the Q&A tab at the top left of the webinar tool bar
 “Click”  in the white space
 “Type” your question
 “Click” ask
 On the Phone
 Press Star (*) 1 to enter the queue
 State your name
 Listen for the operator to call your name 
 State your organization and then ask your question
Thank you for joining!
Please email us questions at coca@cdc.gov
Centers for Disease Control and Prevention 
Atlanta, Georgia
http://emergency.cdc.gov/coca 
Continuing Education for COCA Calls
Continuing Education guidelines require that the attendance of all who 
participate in COCA Conference Calls be properly documented. All 
Continuing Education credits/contact hours (CME, CNE, CEU, CECH, ACPE 
and AAVSB/RACE) for COCA Conference Calls/Webinars are issued online 
through the CDC Training & Continuing Education Online system 
(http://www.cdc.gov/TCEOnline/).
Those who participate in the COCA Conference Calls and who wish to 
receive CE credit/contact hours and will complete the online evaluation by 
June 4, 2016 will use the course code WC2286. Those who wish to receive 
CE credits/contact hours and will complete the online evaluation between 
June 5, 2016 and June 4, 2017 will use course code WD2286. CE 
certificates can be printed immediately upon completion of your online 
evaluation. A cumulative transcript of all CDC/ATSDR CE’s obtained through 
the CDC Training & Continuing Education Online System will be maintained 
for each user. 
Upcoming COCA Call:
CDC Guideline for Prescribing Opioids for Chronic Pain (second 
call in a series of 4)
 Date: Wednesday, July 27, 2016
 Time: 2:00 – 3:00 pm (Eastern Time)
Free Continuing Education. Registration Not Required.
http://emergency.cdc.gov/coca
Join Us on 
Facebook
CDC Facebook page for 
clinicians! “Like” our page 
today to learn about 
upcoming COCA Calls, CDC 
guidance and 
recommendations, and 
about other health alerts
CDC Clinician Outreach and Communication Activity
https://www.facebook.com/CDCClinicianOutreachAndCommunicationActivity
